G Protein News and Research

RSS

NIA awards Aphios Phase I Fast Track SBIR grant for development of novel AD nanodrug

Aphios® Corporation today announced that it was awarded Phase I of a Fast Track SBIR grant from the National Institute of Aging (NIA), National Institutes of Health (NIH) for Developing a Novel Alzheimer's Disease Nanodrug.

30 Nov 2010

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

A new finding out in the December 1st issue of Genes & Development offers insight into a new treatment avenue for two painful inflammatory diseases: Crohn's Disease and sarcoidosis.

30 Nov 2010

Scientists identify signaling pathway and receptor for thymosin beta 4

RegeneRx Biopharmaceuticals, Inc. nnounced that scientists have identified a long sought-after extracellular signaling pathway and receptor for thymosin beta 4 (Tβ4). The observation that Tβ4 increases cell surface ATP (energy produced by cells), could explain its ability to protect and regenerate tissue after ischemic injury and hypoxia (oxygen deficiency).

30 Nov 2010

New review from JASN highlights hazards of fructose

More and more people have become aware of the dangers of excessive fructose in diet. A new review on fructose in an upcoming issue of the Journal of the American Society of Nephrology (JASN) indicates just how dangerous this simple sugar may be.

30 Nov 2010

CAMH neuroscientists develop novel protein peptide for targeted treatment of depression

Neuroscientists at the Centre for Addiction and Mental Health (CAMH) have developed a protein peptide that may be a novel type of highly targeted treatment for depression with a low side-effect profile. Depression affects one in ten Canadians at some time in their lives and is a leading cause of disability worldwide.

30 Nov 2010

Molecular switch plays crucial role in addictive behavior and memory processes

Learning and memory formation are based on the creation of new connections between neurons in the brain. Also, behaviors such as nicotine addiction manifest themselves in long-term changes of neuronal connectivity and can - at least in this respect - be viewed as a form of learning.

30 Nov 2010

GeoVax supports Bionor's Phase 2b trial of therapeutic HIV/AIDS vaccine

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), announced it was pleased to learn of the partial success observed in the recently completed Phase 2b trial of a therapeutic HIV/AIDS vaccine produced by Bionor Immuno AS of Oslo, Norway.

30 Nov 2010

RCSI researchers discover potential new target for diarrhoea associated intestinal diseases

A study by researchers in the Royal College of Surgeons in Ireland (RCSI) has uncovered a potential new target for the treatment of a range of intestinal diseases that are associated with diarrhoea. Current medications are often ineffective and can have serious side effects so this discovery gives hope for the development of new treatments for sufferers of intestinal disease.

30 Nov 2010

Scientists uncover new regulatory mechanism in body's response to eliminate pathogens

A team of scientists from The Scripps Research Institute have uncovered a previously unknown regulatory mechanism in the body's response to eliminate pathogens, such as bacteria and viruses. The findings challenge a long-held dogma in the field of immunology and have potential implications for far-ranging topics from how vaccines should be administered to the origin of autoimmunity.

30 Nov 2010

Research finds alteration in KBTBD13 protein causes nemaline myopathy

Researchers from the Department of Anesthesiology, Uniformed Services University of the Health Sciences (USU), along with research teams from the National Institutes of Health and from Australia, the Netherlands and Spain, have identified a novel gene on chromosome 15q that, when altered, causes nemaline myopathy with cores, a rare inherited muscle disorder. The gene encodes a member of the BTB/Kelch family of proteins.

30 Nov 2010

Case Western Reserve University grants Thermalin Diabetes exclusive license on portfolio of insulin analogs

Case Western Reserve University has granted an exclusive license on a portfolio of insulin analogs to Thermalin Diabetes, LLC, which has assembled more than $3 million to support the development of these important new drugs.

30 Nov 2010

Scientists discover M3-protein can help maintain blood sugar levels

Medical scientists at the University of Leicester have identified for the first time a new way in which our body controls the levels of sugar in our blood following a meal.

30 Nov 2010

Life Technologies launches Qubit 2.0 Fluorometer for molecular biology research

Life Technologies Corporation, a provider of innovative life science solutions, today announced the launch of its next-generation Qubit® 2.0 Fluorometer specifically for molecular biology researchers who work with precious samples and perform applications that require a large financial or time investment. The new system quantitates DNA, RNA and protein with accuracy, sensitivity, speed and ease-of-use.

29 Nov 2010

Weight Watchers introduces PointsPlus weight loss program in the U.S.

The new era of Weight Watchers is here. Today Weight Watchers, the world-renowned leader in weight management, has announced it is introducing in the United States a successor to its popular POINTS weight loss system–the new PointsPlus program.

29 Nov 2010

New 'canSAR' cancer drug discovery database launched

A powerful new cancer drug discovery database has been launched to speed up the process of bringing drugs from 'bench to bedside'.

29 Nov 2010

Marcus evans Summit highlights potential growth, innovation in drug discovery

Drug discovery scientists need to broaden their approaches to pharmaceutical research and development (R&D) and Medicinal Chemistry, to take advantage of untapped opportunities, says Torsten Hoffmann, Head Discovery Chemistry at F. Hoffmann La Roche, Basel, Switzerland. Chemical Biology allows room for innovation, but is often overlooked by scientists in the industry.

29 Nov 2010

JAK3 pathway highlighted as leukemia target

An intriguing study published in Expert Review of Anticancer Therapy has revealed that the signaling protein JAK3 represents a viable target in the treatment of a broad range of B-lineage cancers, including acute lymphoblastic leukemia (ALL).

28 Nov 2010

NIH awards $6.7M to establish Membrane Protein Structural Biology Consortium

Dr. Michael G. Malkowski, Hauptman-Woodward senior research scientist, has received a $6.7 million grant from the National Institutes of Health in support of his work to establish the Membrane Protein Structural Biology Consortium (mpsbc.org) as one of nine centers in the United States responsible for determining membrane protein structures within a larger NIH biology-based initiative.

26 Nov 2010

New findings provide insight into brain development

St. Jude Children's Research Hospital investigators have identified key components of a signaling pathway that controls the departure of neurons from the brain niche where they form and allows these cells to start migrating to their final destination. Defects in this system affect the architecture of the brain and are associated with epilepsy, mental retardation and perhaps malignant brain tumors.

25 Nov 2010

Looking back and moving forward: 100 years of Pneumococcal vaccination

"Since the introduction of smallpox vaccination by Sir Edward Jenner in 1796, it took 184 years until the WHO could declare the world free of smallpox. How long will it take to eliminate pneumococcus from the world?"

25 Nov 2010